The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
Subscribe To Our Newsletter & Stay Updated
